Efficacy Evaluation of Bevacizumab Combined with Capecitabine in the Treatment of HER2-Negative Metastatic Breast Cancer: A Meta-Analysis

Table 1

Basic information of patients included in the study.

Authors	Study type	Sample size		Age		Therapeutic regimen		Subgroup	Outcome indicators
		E	C	E	C	E	C
Gligorov et al. [14]	RCT	91	94	49 (24–80)	54 (24–77)	Bevacizumab + capecitabine	Bevacizumab	1	①②③④
Bear et al. [15]	RCT	204	201	39.6 (/–/)	40.3 (/–/)	Bevacizumab + capecitabine-docetaxel	Capecitabine-docetaxel	1	①③⑤
Zielinski et al. [16]	RCT	277	284	≥18	≥18	Bevacizumab + capecitabine	Bevacizumab + paclitaxel	2	①②③④
Lang et al. [17]	RCT	279	285	59 (48–65)	59 (49–65)	Bevacizumab + capecitabine	Bevacizumab + paclitaxel	2	①②③④⑤
Brufsky et al. [18]	RCT	97	47	57 (31–78)	50 (23–90)	Bevacizumab + capecitabine	Capecitabine + placebo	1	①②③⑤
Decker et al. [19]	RCT	39	38	64.4 (47–83.6)	65.9 (49.8–86)	Bevacizumab + capecitabine	Everolimus + exemestane	1	①②③④
Lam et al. [8]	RCT	156	156	56 (32–76)	56 (34–74)	Bevacizumab + capecitabine-docetaxel	Capecitabine-docetaxel	1	①②③④⑤
Luck et al. [20]	RCT	111	111	56.2 (31–78)	57 (33–80)	Bevacizumab + capecitabine-taxanes	Bevacizumab-taxanes	2	①②④

E, experimental group; C, control group; RCT, randomized controlled trial; /, no data; subgroup 1, control group (non-bevacizumab and chemotherapy drug combination); subgroup 2, control group (bevacizumab and chemotherapy drug combination). Outcome measures: ① disease progression rate; ② disease progression-free survival; ③ 1-year survival rate; ④ incidence of adverse events; ⑤ objective remission rate.